Abstract
Bisphosphonates have been widely used over the past decade to prevent skeletal complications in breast cancer patients with bone metastases. The skeletal complications associated with bone metastases include severe bone pain, pathologic fractures, spinal cord compression, and hypercalcemia. A number of bisphosphonates, including oral clodronate, intravenous (IV) pamidronate, IV zoledronic acid, and ibandronate have been shown to significantly reduce skeletal complications and palliate bone pain in patients with breast cancer based on placebo-controlled trials. However, only zoledronic acid and pamidronate have been directly compared within a single trial, and zoledronic acid (4 mg via 15- minute infusion) was shown to be significantly more effective than 90 mg pamidronate at reducing the overall risk of skeletal complications in patients with breast cancer. Both IV pamidronate and zoledronic acid are recommended by the American Society of Clinical Oncology for the treatment of malignant bone disease. As we look to the future, the role of bisphosphonates will continue to evolve beyond the prevention of skeletal complications. Encouraging results have recently been reported from studies assessing the effects of bisphosphonates on tumor progression in bone and for the prevention of cancer treatment-induced bone loss.
Keywords: breast cancer, skeletal complications, zoledronic acid, ibandronate, pamidronate, clodronate
Current Cancer Therapy Reviews
Title: Bisphosphonate Therapy for Patients with Breast Cancer
Volume: 1 Issue: 3
Author(s): Allan Lipton
Affiliation:
Keywords: breast cancer, skeletal complications, zoledronic acid, ibandronate, pamidronate, clodronate
Abstract: Bisphosphonates have been widely used over the past decade to prevent skeletal complications in breast cancer patients with bone metastases. The skeletal complications associated with bone metastases include severe bone pain, pathologic fractures, spinal cord compression, and hypercalcemia. A number of bisphosphonates, including oral clodronate, intravenous (IV) pamidronate, IV zoledronic acid, and ibandronate have been shown to significantly reduce skeletal complications and palliate bone pain in patients with breast cancer based on placebo-controlled trials. However, only zoledronic acid and pamidronate have been directly compared within a single trial, and zoledronic acid (4 mg via 15- minute infusion) was shown to be significantly more effective than 90 mg pamidronate at reducing the overall risk of skeletal complications in patients with breast cancer. Both IV pamidronate and zoledronic acid are recommended by the American Society of Clinical Oncology for the treatment of malignant bone disease. As we look to the future, the role of bisphosphonates will continue to evolve beyond the prevention of skeletal complications. Encouraging results have recently been reported from studies assessing the effects of bisphosphonates on tumor progression in bone and for the prevention of cancer treatment-induced bone loss.
Export Options
About this article
Cite this article as:
Lipton Allan, Bisphosphonate Therapy for Patients with Breast Cancer, Current Cancer Therapy Reviews 2005; 1 (3) . https://dx.doi.org/10.2174/157339405774574261
DOI https://dx.doi.org/10.2174/157339405774574261 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Biodistribution of LV-TSTA Transduced Rat Bone Marrow Cells Used for “Ex-vivo” Regional Gene Therapy for Bone Repair
Current Gene Therapy Stem Cell Therapy for Spinal Cord Injury
Current Medicinal Chemistry Agonists of the Tissue-Protective Erythropoietin Receptor in the Treatment of Parkinson’s Disease
Current Topics in Medicinal Chemistry Emerging and New Treatment Options for Knee Osteoarthritis
Current Rheumatology Reviews Cellular Signalling Pathways of Spinal Pain Neuroplasticity as Targets for Analgesic Development
Current Topics in Medicinal Chemistry Role of the Cannabinoid System in Pain Control and Therapeutic Implications for the Management of Acute and Chronic Pain Episodes
Current Neuropharmacology Bone Target Radiotracers for Palliative Therapy of Bone Metastases
Current Medicinal Chemistry Bone Marrow Concentrate: A Novel Strategy for Bone Defect Treatment
Current Stem Cell Research & Therapy Protective Effects of Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) Against Apoptosis
Current Pharmaceutical Design Extranuclear Localization of SIRT1 and PGC-1α: An Insight into Possible Roles in Diseases Associated with Mitochondrial Dysfunction
Current Molecular Medicine <sup>18</sup>F-labeled Bisphosphonate as an Alternative Candidate to the Gold Standard[<sup>18</sup>F]sodium fluoride ([<sup>18</sup>F]NaF) for PET Bone Imaging
Current Medical Imaging Development of Multifunctional Nanoparticles for Targeted Drug Delivery and Noninvasive Imaging of Therapeutic Effect
Current Drug Discovery Technologies Medical and Dental Implications of Down Syndrome: A Review Part 1: General and Craniofacial Characteristic
Applied Clinical Research, Clinical Trials and Regulatory Affairs P2X4 Receptors of Microglia in Neuropathic Pain
CNS & Neurological Disorders - Drug Targets Neutralizing Endogenous VEGF Following Traumatic Spinal Cord Injury Modulates Microvascular Plasticity but not Tissue Sparing or Functional Recovery
Current Neurovascular Research Reversal of Bone Cancer Pain by HSV-1-Mediated Silencing of CNTF in an Afferent Area of the Spinal Cord Associated with AKT-ERK Signal Inhibition
Current Gene Therapy Secondary Brain Injuries in Thalamus and Hippocampus after Focal Ischemia Caused by Mild, Transient Extradural Compression of the Somatosensori Cortex in the Rat
Current Neurovascular Research Global Cerebral Ischemia: Synaptic and Cognitive Dysfunction
Current Drug Targets Melanoma: The Radiotherapeutic Point of View; Review of the Current Literature
Reviews on Recent Clinical Trials The Pleiotropic Effects of Inducible Nitric Oxide Synthase (iNOS) on the Physiology and Pathology of Penile Erection
Current Pharmaceutical Design